Sclerostin Antikörper (Middle Region)

Produktnummer ABIN358752

Dieser Anti-Sclerostin-Antikörper ist ein Kaninchen-Polyklonal-Antikörper zum Nachweis von Sclerostin in WB, IHC (p) und EIA. Geeignet für Human.

Kurzübersicht für Sclerostin Antikörper (Middle Region) (ABIN358752)

Target: Sclerostin (SOST)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Sclerostin Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Produktdetails anti-Sclerostin Antikörper

Bindungsspezifität: AA 141-171, Middle Region

Spezifität: This antibody recognizes SOST (Center).

Aufreinigung: Protein A Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS

Immunogen: KLH conjugated synthetic peptide between 141~171 amino acids from the Center region of Human SOST.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: ELISA: 1/1,000. Western Blot: 1/50-1/100Immunohistochemistry: 1/10-1/50.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.25 mg/mL

Buffer: PBS with 0.09 % (W/V) Sodium Azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Details zu Sclerostin

Target: Sclerostin (SOST)

Andere Bezeichnung: Sclerostin / SOST

Hintergrund: Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of the sclerostin gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.

Gen-ID: 50964, 9606

UniProt: Q9BQB4